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Adenosine triphosphate (ATP) and other nucleotides and nucleosides, such 
as adenosine, are signaling molecules involved in many physiological and patho-
physiological processes. The group of cell and tissue responses mediated by these 
molecules is known as purinergic signaling. Ecto-nucleotidases are ectoenzymes 
expressed at the cell membrane that act sequentially to efficiently hydrolyze 
extracellular ATP into adenosine, and they are key elements of this signaling. There 
is growing interest in studying these enzymes in relation to various pathologies, 
especially those with an inflammatory component such as cancer. This review 
summarizes the main protocols for the study of the expression and in situ activity of 
ectoenzymes in tissue slices and cultured cells.
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1. Introduction
In this chapter, we intend to detail basic protocols for the in situ detection of 
ecto-nucleotidases as an introduction to the technique for those who have never 
made these experimental approaches. This chapter does not aim to be a review 
on ecto-nucleotidases because there are already excellent highly recommended 
reviews [1–4].
Ecto-nucleotidases are broadly expressed enzymes active in almost all tissues 
of all organisms, both animals and plants. What varies among the cell (and tissue) 
types are the subtype(s) of enzyme(s) and the combination of them, expressed in 
a particular cell type. In general, these enzymes convert adenosine triphosphate 
(ATP), as well as diphosphate (ADP) and monophosphate (AMP), into adenosine. 
In situ detection of these enzymes confers functional sense on immunodetec-
tion studies. It is also a convenient tool for the validation of new inhibitors of 
these enzymes, which can be studied in the cell context of the tissue where they 
are found. The study of ecto-nucleotidases and their inhibitors (many of them 
antibodies) is at the center of oncological research to therapeutically target the 
adenosinergic pathway, a fact reflected in the increased number of high impact 
publications in the field.
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The technique is feasible because ecto-nucleotidases maintain their activity 
of hydrolyzing nucleotides in formalin-fixed frozen tissues (and cells). Inorganic 
phosphorous (Pi) generated upon their activity combines with a lead salt added to 
the reaction mixture, forming brown precipitates in the places where the enzymes 
are active, which can be visualized under light microscope. The protocol, with slight 
modifications, can also be used for electron microscopy.
There are four families of membrane-bound ecto-nucleotidases. Other nucleo-
tidases act intracellularly but are not studied here. The main features of ecto- 
nucleotidases are included in Figure 1 and summarized below.
1.1 Ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases)
The E-NTPDase family is composed of eight members, four of which are cell 
surface-located: NTPDase1, also known as CD39; NTPDase2 or CD39L1; NTPDase3 
or CD39L3; and NTPDase8. They perform the ATP (and ADP) hydrolysis to AMP 
with different ADP production abilities. These differences between enzymes reflect 
 different consequences in cells depending on the ATP receptors expressed [5]. 
The four members display similar structural properties, with two transmembrane 
domains, close to the N and C terminus, and a catalytic extracellular domain [3]. 
They require millimolar concentrations of Mg2+ and Ca2+ ions in order to perform ATP 
hydrolysis, and the absence of these ions results in no enzymatic activity. All of them 
hydrolyze nucleoside triphosphates (NTP), but they differ in substrate  specificity. 
NTPDase1 hydrolyzes ATP and ADP equally, while NTPDase3 and NTPDase8 
hydrolyze ATP or uridine triphosphate (UTP) more efficiently than ADP or uridine 
diphosphate (UDP). Finally, the NTPDase2 is the most ATP-specific NTPDase, and 
for this reason it is also named the ecto-ATPase [2].
Most of the available NTPDase inhibitors are ATP analogues such as ARL-67156 
and PSB-6426, a potent NTPDase2 inhibitor. Non-nucleotide-based inhibitors also 
described in literature are compounds related to dyes bearing sulfonate groups such 
Figure 1. 
Schematic representation of the four families of membrane-bound ecto-nucleotidases and their substrate 
specificities. E-NTPDases, ecto-nucleoside triphosphate diphosphohydrolases; E-NPPs, ecto-nucleotide 
pyrophosphatase/phosphodiesterases; ecto-5’-NT, ecto-5’-nucleotidase; APs, alkaline phosphatases; NTP, 
nucleoside triphosphate; NDP, nucleoside diphosphate; NMP, nucleoside monophosphate; cNMP, cyclic 
nucleoside monophosphate; N, nucleoside.
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as suramin, a nonselective inhibitor, and the pyridoxal phosphate-6-azophenyl-
2′,4′-disulfonic acid (PPADS). Other inhibitors are the polyoxometalates, such as 
POM 1 [6]. Inhibitory antibodies, mainly against CD39, are being developed for use 
in cancer therapy [7].
1.2 Ecto-nucleotide pyrophosphatases/phosphodiesterases (E-NPPs)
The E-NPP family represents a versatile group of seven structurally related 
enzymes with pyrophosphatase and phosphodiesterase activities having a wide 
range of hydrolysable substrates. The membrane-bound ectoenzymes NPP1 and 
NPP3 and the secreted NPP2 are the most studied members. Catalytic activity 
of E-NPPs is composed of a two-step hydrolysis consisting of a first attack on 
the phosphate of the incoming substrate by a threonine/serine metal-activated 
catalytic site and a second attack on the intermediate substrate by a metal-
activated site, thus releasing a nucleoside 5′-monophosphate. In general, NPP1–3 
are typed as alkaline ecto-nucleotide pyrophosphatases that hydrolyze a number 
of phosphodiester bonds (e.g., from oligonucleotides, lysophosphatidylcholine, 
sphingomyelin, and glycerophosphorylcholine or from artificial substrates like 
the p-nitrophenyl 5′-thymidine monophosphate (p-Nph-5′-TMP)) and pyrophos-
phate bonds (e.g., from (d)NTPs, (d)NDPs, NAD, FAD, and UDP sugars or from 
artificial substrates like the thiamine pyrophosphate (TPP)) to generate nucleoside 
5′-monophosphates. TPP is the “false” substrate mainly used for NPP identifica-
tion in in situ activity assays. Like most of the enzymes, E-NPPs can be inhibited 
in vitro by the substrates and products of the NPP reaction, as well as by heparin 
and heparan sulfate glycosaminoglycans, and by other substances such as imidaz-
ole, 2-mercaptoethanol, and metal ion-chelating agents [8]. Anti-NPP3 inhibitory 
antibody represents a promising therapeutic tool for the treatment of renal cell 
carcinoma [9].
1.3 Ecto-5′-nucleotidase (ecto-5′-NT, eN)/CD73
Extracellular AMP resulting from the hydrolysis of ATP and ADP by most of 
the ecto-nucleotidases can in turn be efficiently hydrolyzed into adenosine by eN, 
a glycosylphosphatidylinositol-linked membrane-bound glycoprotein also known 
as CD73 [10], which hydrolyses nucleotide-5′-monophosphates (NMP) [3]. It is 
broadly expressed as an alpha dimer bound with disulfide bridges and shows differ-
ent functions depending on the cell type. Although eN activity is ion-independent 
in physiological conditions, in vitro the presence of Mg2+ ions can considerably 
increase its ability to hydrolyze AMP. In addition to its AMPase activity, eN hydro-
lyzes 2-deoxyribose compounds but much less effectively than AMP. Unlike other 
ectoenzymes such as NPPs, eN is not inhibited by Pi. Alpha,beta-methylene-ADP and 
some of its derivatives and analogues are efficient inhibitors [11]. Inhibitory anti-
CD73 antibodies are used in clinical trials [7].
1.4 Alkaline phosphatases (APs)
Phosphatases are a superfamily of proteins that mediate the phosphate removal 
of proteins and other substrates [12]. Depending on their substrate specificity, they 
are divided into two major groups: the protein phosphatases, which mediate the 
hydrolysis of phosphate groups from protein residues (e.g., serine/threonine phos-
phatases), and the membrane-bound phosphatases, which mediate the hydrolysis 
of phosphate groups from nonprotein substrates (e.g., acid and alkaline phospha-
tases). In this chapter, we are focusing on the membrane-bound phosphatases, in 
particular the AP family [12, 13].
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APs are zinc-containing dimeric membrane-bound glycoproteins that require 
magnesium ion for the hydrolysis of a wide range of phosphomonoesters. Although 
optimum activity occurs at alkaline pH (9.3–10.3), they are also active at a physi-
ological pH, and they are primarily responsible for the PPi phosphohydrolysis in 
neutral and alkaline environments. APs are classified by their tissue expression and 
distribution [14]; in humans there are four types of APs in two main groups: the 
tissue nonspecific alkaline phosphatase (TNAP), with only one member, and the 
tissue-specific APs, which include the placental-like alkaline phosphatase (PLAP), 
the germ cell alkaline phosphatase (GCAP), and the intestinal alkaline phosphatase 
(IAP). Despite the fact that TNAP expression is not tissue-specific, it is mainly 
found in the liver, bone, and kidneys [15].
APs catalyze the hydrolysis of monoesters of phosphoric acids and have exten-
sive substrate specificity in vitro. For example, TNAP is able to hydrolyze ATP, 
ADP, AMP, PPi, glucose-1-phosphate, glucose-6-phosphate, fructose-6-phosphate, 
and β-glycerophosphate; however, only a few compounds have been considered as 
natural in vivo AP substrates, like PPi, pyridoxal-5′-phosphate (PLP or vitamin B5), 
and phosphoethanolamine (PEA). APs by themselves are extremely efficient 
ATPase enzymes, but an autoregulatory mechanism has been described in order to 
modify the substrate specificity depending on the environmental concentrations of 
free inorganic phosphates or cell and tissue demands. Pi itself is known to inhibit 
the hydrolytic activity through a competitive mechanism, and therefore Pi levels 
will impact the ability of AP to hydrolyze PPi [15, 16]. Levamisole is an inhibitor 
of the APs. Because of the ability to cleave all forms of adenosine phosphates, APs 
significantly influence purinergic signaling [17].
2. In situ nucleotidase activity experiments
The protocol detailed here for the detection of E-NTPDases, E-NPPs, and eN is 
based on the Wachstein-Meisel lead phosphate method [18], and the protocol for 
AP identification is based on the Gossrau method [19], with some modifications.
2.1 Wachstein-Meisel lead phosphate-based method
2.1.1 In tissue samples
Tissue pieces are fixed with 4% paraformaldehyde for a time period varying 
from a few hours to 2 days depending on the size (Figure 2). Following fixation, tis-
sue pieces are cryopreserved by embedding them in 30% sucrose (in Milli-Q H2O) 
O/N or until tissue sinks. Tissues are then embedded in optimum cutting tempera-
ture (OCT) compound and cut with a cryostat into 15 μm-thick sections that are 
put on slides. It is recommended that pretreated slides be used, either homemade 
polylysine-treated or the commercial ones, to eliminate tissue loss during the 
procedure. Sections are stored at −20°C until use.
Tissue slides are rinsed with phosphate buffered saline (PBS) to remove OCT 
compound and washed twice with 50 mM Tris-maleate buffer pH 7.4 at RT. Slides 
are then incubated for 30 min at RT with preincubation buffer (50 mM Tris-maleate 
buffer pH 7.4 containing 2 mM MgCl2 and 250 mM sucrose) and then for 1 h at 37°C 
with the enzyme reaction buffer (50 mM Tris-maleate buffer pH 7.4 supplemented 
with 250 mM sucrose, 2 mM MgCl2, 5 mM MnCl2, 2 mM Pb(NO3)2, and 2 mM 
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Figure 2. 
Scheme including the main steps of the lead phosphate-based method for ecto-nucleotidase activity detection.
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CaCl2 and stabilized with 3% Dextran T-250) in the presence or absence of nucleo-
tide as substrate (e.g., ATP). The incubation time and the substrate concentration 
may vary depending on the experiment, but 1 h at 1 mM is generally suitable. To 
avoid interference with AP activity, experiments are performed in the presence of 
the inhibitor levamisole (2.5 mM). Note that the optimum pH for APs is 9, but they 
are also active at a pH of 7.4. The reaction is stopped with dH2O and revealed by 
incubating with 1% (NH4)2S v/v for exactly 1 min. A control slide in the absence of 
nucleotide, in which no reaction is expected, is included in the experiment. Nuclei 
are counterstained with hematoxylin. Samples are then mounted with aqueous 
mounting medium (e.g., Fluoromount™, Sigma-Aldrich); dehydration is not 
recommended because of the eventual loss of lead precipitates. Finally, samples 
are observed and photographed under light microscope; enzyme-active sites are 
brownish black. An adapted protocol with slight modifications, including the 
replacement of ammonium sulfide by glutaraldehyde, can be applied for electron 
microscopy [20]. Table 1 includes buffer formulations.
Besides levamisole, enzyme inhibitors might be included in both preincubation 
and incubation buffers. For example, 1 mM α,β-methylene-ADP efficiently inhibits 
CD73, and POM 1 inhibits NTPDases (Figure 3).
Table 1. 
Formulation of buffers used for the lead phosphate-based method. The most right column includes the reagent 
amounts calculated to prepare a 1 mL final volume (FV) solution. Different nucleotides can be used as 
substrate. Inhibitors can also be added to both preincubation and reaction buffers; H2O to adjust the volume 
must then be modified accordingly.
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2.1.2 In cell cultures
Cells are seeded onto coverslips and allowed to grow with their regular medium 
until the desired confluence is achieved. The medium is then removed, and the cells 
are washed twice with PBS before fixation with 4% paraformaldehyde for 5–10 min 
at RT. Cells are washed three times with PBS to wash out the fixative and kept at 4°C 
with PBS until use. To proceed with the protocol, coverslips are washed twice for 
5 min with gentle rocking with 50 mM Tris-maleate buffer pH 7.4 at RT and then 
incubated for 30 min at RT with the preincubation buffer. The following steps are as 
reported for the tissue slices.
2.2 Gossrau-based method for APs
In situ localization of APs can be addressed by using the Gossrau method that 
utilizes nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP) as artificial substrates for the APs. Briefly, tissue slices or fixed cells grown on 
coverslips are washed twice in 0.1 M Tris–HCl buffer pH 7.4 containing 5 mM MgCl2 
and then preincubated with the same buffer at pH 9.4 for 15 min at RT. Enzymatic 
reaction starts by adding the revealing reagent BCIP/NBT (Sigma-Aldrich) for 7 min 
(up to 15 min) at RT and stopped with 0.1 M Tris–HCl buffer pH 7.4. In AP inhibi-
tion experiments, 5 mM levamisole can be added to both preincubation and enzyme 
reaction buffers. In control experiments, the revealing reagent is omitted. Since the 
reaction generates blue precipitates, nuclei staining with hematoxylin should be 
avoided. Alternatively nuclei can be counterstained with methyl green dye. Samples 
are then mounted with aqueous mounting medium (e.g., Fluoromount™, Sigma-
Aldrich) and observed and photographed under light microscope.
Figure 3. 
(A) In situ AMPase activity in the endometrial carcinoma human HEC-1B cell line in the presence of 1 mM 
AMP (a). Note that most of the activity is located at the cell membrane, where CD73 is expressed. Incubation 
in the presence of the inhibitor α,β-methylene-ADP (α,β-meADP) drastically diminished the activity (b). No 
AMPase activity is detected when AMP is omitted in the reaction (c). (B) In situ enzyme ATPase activity in 
human endometrium in the presence of 1 mM ATP (a). Activity is strongly inhibited with the NTPDase inhibitor 
POM 1 (b). No ATP activity is detected when ATP is omitted (c). Scale bars are 50 μm (a) and 200 μm (B).
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Figure 4. 
Scheme including the main steps of the method combining immunofluorescence and in situ ecto-nucleotidase 
activity detection protocols.
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2.3 Combined immunolabeling and in situ nucleotidase activity experiments
The technique uses the same tissue slide (or the same coverslip of cells) to 
identify both the activity, with in situ histochemistry (or cytochemistry), and the 
protein, with immunofluorescence (Figure 4) [21, 22]. Tissue sample sections or 
fixed cells grown on coverslips are washed twice with PBS and incubated with a 
blocking solution containing 20% normal goat serum and 0.2% gelatin in PBS at 
RT for 1 h and then incubated O/N at 4°C with the appropriate primary antibody. 
The samples are washed three times with PBS and twice with 50 mM Tris-maleate 
buffer. In situ nucleotidase activity experiment is performed as detailed previously, 
adding the appropriate nucleotide as substrate. Subsequently, the tissues are washed 
three times in PBS before incubating with the appropriate fluorescent-labeled 
secondary antibody. After three final washes with PBS, nuclei are labeled, and the 
samples mounted with aqueous mounting medium; a mounting medium containing 
DAPI can be used for this purpose (e.g., ProLong Gold antifade reagent with DAPI 
mounting medium from Thermo Fisher Scientific). The sections are observed and 
photographed under a Nikon Eclipse E800 Microscope. Pictures of bright field (for 
activity) and fluorescence (for protein immunolocalization and nuclei visualiza-
tion) are taken sequentially from the same field.
We recommend that histochemistry be performed between primary and sec-
ondary antibody incubations, but other protocols are also feasible. This is of interest 
when using inhibitory antibodies. In these cases the in situ histochemistry should 
be performed at the beginning of the procedure. It also has to be taken into account 
that it might be necessary to test different nucleotide concentrations and incubation 
times in order to optimize the results for a particular tissue in order to minimize 
hampering of fluorescence capture by the dark brown lead deposits.
Figures 5 and 6 are examples of this combined technique in tissue and cell 
culture, respectively. Figure 5 shows immunofluorescence to localize NTPDase1, 
and in situ histochemistry for the ADPase activity in human fallopian tubes. The 
Figure 5. 
Immunolocalization of NTPDase1 (a, d) and in situ ADPase histochemistry (b, e) in cryosections of human 
oviducts. NTPDase1 was detected with immunofluorescence in endothelial cells of lamina propria (a) and 
in smooth muscle cells (d). Microphotographs b and e show dark brown deposits corresponding to in situ 
ADPase activity. Merge images (c, f) confirmed that NTPDase1 is active in the same structures where it 
immunolocalizes. Reddish structure at top right of image is the blood inside the vessel. Scale bar is 25 μm. 
Reprinted by permission of springer nature histochemistry and cell biology, characterization of ecto-
nucleotidases in human oviducts with an improved approach simultaneously identifying protein expression an 
in situ enzyme activity, Villamonte et al. [21].
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antibodies used were mouse antihuman NTPDase1 primary antibody (clone BU-61, 
Ancell) and Alexa Fluor 488 goat anti-mouse secondary antibody (Thermo Fisher 
Scientific). Label is seen together with the lead precipitate in endothelium of blood 
vessels, especially abundant in the lamina propria of the mucosa layer, and in mus-
cle cells, predominant in the muscular layer [21]. In Figure 6, the antibody against 
human placental-like alkaline phosphatase (PLAP; clone 8B6, Sigma-Aldrich) was 
used in Ishikawa cells to localize the protein by immunofluorescence, together with 
the activity obtained with the BCIP/NBT reagent.
3. Conclusions
In conclusion, in situ histochemistry for ecto-nucleotidases is an easy-to- 
perform, reproducible technique suitable for tissues and cells. The combined 
technique allows identification of the protein that has a precise enzyme activity. The 
technique is suitable for testing enzyme inhibitors.
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Placental-like alkaline phosphatase (PLAP) immunofluorescence (a) and in situ enzyme AP activity (b) in 
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scale, and in consequence blue deposits are visualized in black. Scale bar is 25 μm.
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